Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection

This publication has 18 references indexed in Scilit:

• Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab
  British Journal of Haematology, 2002
• Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
  Blood, 2002
• Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
  Medical Oncology, 2002
• Fatal Adenovirus Infection During Alemtuzumab (Anti-CD52 Monoclonal Antibody) Treatment of a Patient with Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
  Medical Oncology, 2002
• Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation
  Bone Marrow Transplantation, 2001
• Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy
  British Journal of Haematology, 2001
• CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
  Journal of Clinical Oncology, 1998
• Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
  Journal of Clinical Oncology, 1997
• Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia
  British Journal of Haematology, 1997
• The CAMPATH‐1 antigen (CDw52)
  Tissue Antigens, 1990